HK1243130A1 - 微小核糖核酸化合物及調節mir-21活性的方法 - Google Patents

微小核糖核酸化合物及調節mir-21活性的方法

Info

Publication number: HK1243130A1
Authority: HK; Hong Kong
Prior art keywords: activity; methods; modulating mir; microrna compounds; microrna
Prior art date: 2011-04-25

Application number

HK18102629.5A

Other languages

English (en)

Inventor

Balkrishen Bhat

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-25

Filing date

2018-02-23

Publication date

2018-07-06

2018-02-23 Application filed by Sanofi Sa filed Critical Sanofi Sa

2018-07-06 Publication of HK1243130A1 publication Critical patent/HK1243130A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Hematology (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)

HK18102629.5A 2011-04-25 2018-02-23 微小核糖核酸化合物及調節mir-21活性的方法 HK1243130A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161478767P	2011-04-25	2011-04-25
US201161565779P	2011-12-01	2011-12-01

Publications (1)

Publication Number	Publication Date
HK1243130A1 true HK1243130A1 (zh)	2018-07-06

Family

ID=46025979

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18102629.5A HK1243130A1 (zh)	2011-04-25	2018-02-23	微小核糖核酸化合物及調節mir-21活性的方法

Country Status (31)

Country	Link
US (7)	US9181547B2 (zh)
EP (3)	EP3933040A1 (zh)
JP (2)	JP6320292B2 (zh)
KR (2)	KR102055172B1 (zh)
CN (3)	CN113249381A (zh)
AU (4)	AU2012249851B2 (zh)
BR (1)	BR112013027187A2 (zh)
CA (2)	CA3165397A1 (zh)
CL (1)	CL2013003105A1 (zh)
CO (1)	CO6821889A2 (zh)
CY (1)	CY1120304T1 (zh)
DK (2)	DK2702155T3 (zh)
EA (1)	EA025894B1 (zh)
ES (2)	ES2868950T3 (zh)
HK (1)	HK1243130A1 (zh)
HR (2)	HRP20170557T2 (zh)
HU (2)	HUE031595T2 (zh)
IL (3)	IL229032B (zh)
LT (2)	LT2702155T (zh)
MX (5)	MX2013012452A (zh)
MY (2)	MY187685A (zh)
NZ (1)	NZ717921A (zh)
PH (1)	PH12013502199A1 (zh)
PL (2)	PL2702155T3 (zh)
PT (2)	PT3211082T (zh)
RS (1)	RS61775B1 (zh)
SG (1)	SG194636A1 (zh)
SI (2)	SI3211082T1 (zh)
TW (2)	TWI607016B (zh)
UA (1)	UA115652C2 (zh)
WO (1)	WO2012148952A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2503738T3 (es)	2004-11-12	2014-10-07	Asuragen, Inc.	Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
LT2702155T (lt)	2011-04-25	2017-05-10	Regulus Therapeutics Inc.	Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui
WO2013153082A1 (en) *	2012-04-10	2013-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of nonalcoholic steatohepatitis
PH12023550488A1 (en) *	2012-04-25	2024-06-24	Sanofi Sa	Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта
SI2920304T1 (sl)	2012-11-15	2019-06-28	Roche Innovation Center Copenhagen A/S	Oligonukleotidni konjugati
SG11201508925WA (en) *	2013-05-01	2015-11-27	Regulus Therapeutics Inc	Microrna compounds and methods for modulating mir-122
WO2015061536A1 (en) *	2013-10-25	2015-04-30	Regulus Therapeutics Inc.	Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko)	2013-11-18	2016-05-30	울산대학교 산학협력단	ｍｉＲＮＡ 스폰지 및 이의 용도
WO2015113922A1 (en) *	2014-01-30	2015-08-06	Roche Innovation Center Copenhagen A/S	Poly oligomer compound with biocleavable conjugates
CN105734127A (zh) *	2016-02-29	2016-07-06	上海中医药大学	miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) *	2016-04-29	2017-11-02	Aptamir Therapeutics, Inc.	Inhibition of mir-22 mirna by apt-110
US20180193270A1 (en)	2016-11-29	2018-07-12	PureTech Health LLC	Exosomes for delivery of therapeutic agents
JP2020534015A (ja)	2017-09-22	2020-11-26	ユニヴァーシティオブワシントン	細胞分子のｉｎｓｉｔｕコンビナトリアル標識化
CN108148911B (zh) *	2018-03-02	2019-11-05	广州医科大学附属第二医院	miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
CN112400020B (zh)	2018-05-08	2024-11-19	莱古路斯治疗法股份有限公司	作为具有hcv抗病毒活性与降低的高胆红素血症副作用的mir-122抑制剂的galnac缀合的经修饰的寡核苷酸
CN110747266A (zh) *	2018-07-23	2020-02-04	深圳先进技术研究院	miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) *	2019-03-26	2019-06-14	中国人民解放军第八一医院	一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en)	2020-04-16	2024-04-23	The Johns Hopkins University	MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) *	2021-01-29	2022-08-04	Angion Biomedica Corp.	Methods for treatment of fibrotic diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060008817A1 (en) *	2000-12-08	2006-01-12	Invitrogen Corporation	Methods and compositions for generating recombinant nucleic acid molecules
IL161100A0 (en)	2001-09-28	2004-08-31	Max Planck Gesellschaft	Identification of novel genes coding for small temporal rnas
CA2504694C (en)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2533701A1 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
ATE555118T1 (de)	2003-08-28	2012-05-15	Takeshi Imanishi	Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
AU2005272816B2 (en)	2004-08-10	2011-08-11	Alnylam Pharmaceuticals, Inc.	Chemically modified oligonucleotides
ES2503738T3 (es)	2004-11-12	2014-10-07	Asuragen, Inc.	Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1838870A2 (en)	2004-12-29	2007-10-03	Exiqon A/S	NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US6995235B1 (en)	2005-05-02	2006-02-07	Univation Technologies, Llc	Methods of producing polyolefins and films therefrom
WO2007027894A2 (en) *	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Antisense compounds having enhanced anti-microrna activity
EP1984381B1 (en)	2006-01-27	2010-09-29	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
AU2007211082B2 (en)	2006-01-27	2012-09-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
JP5198430B2 (ja)	2006-04-03	2013-05-15	サンタリスファーマアー／エス	ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
EP3502255A1 (en) *	2006-04-03	2019-06-26	Roche Innovation Center Copenhagen A/S	Pharmaceutical composition
KR101129509B1 (ko)	2006-10-03	2012-04-13	알닐람 파마슈티칼스 인코포레이티드	지질 함유 조성물
EP2476762B1 (de)	2006-10-09	2014-01-08	Julius-Maximilians-Universität Würzburg	MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
EP2104735A2 (en)	2006-12-08	2009-09-30	Asuragen, INC.	Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2118118B1 (en)	2007-01-19	2017-09-27	Exiqon A/S	Mediated cellular delivery of lna oligonucleotides
AU2008260277C1 (en)	2007-05-30	2014-04-17	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos carbocíclicos
US20100261175A1 (en)	2007-06-15	2010-10-14	Exiqon A/S	Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
EP2176280B2 (en)	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
DK2205737T3 (da) *	2007-10-04	2013-05-21	Santaris Pharma As	Mikromirer
US8211867B2 (en)	2007-10-29	2012-07-03	Regulus Therapeutics Inc.	Targeting microRNAs for the treatment of liver cancer
US20110257244A1 (en)	2008-01-18	2011-10-20	Alnylam Pharmaceuticals, Inc.	Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2096171A1 (en) *	2008-02-27	2009-09-02	Julius-Maximilians-Universität Würzburg	MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US8404659B2 (en)	2008-03-07	2013-03-26	Santaris Pharma A/S	Pharmaceutical compositions for treatment of MicroRNA related diseases
JP2012518997A (ja) *	2009-02-26	2012-08-23	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法
CA2765129A1 (en) *	2009-06-08	2010-12-16	Miragen Therapeutics	Chemical modification motifs for mirna inhibitors and mimetics
WO2011126842A2 (en)	2010-03-30	2011-10-13	Regulus Therapeutics Inc.	Targeting micrornas for the treatment of cardiac disorders
LT2702155T (lt)	2011-04-25	2017-05-10	Regulus Therapeutics Inc.	Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui
WO2013013165A2 (en)	2011-07-21	2013-01-24	The Trustees Of The University Of Pennsylvania	Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
PH12023550488A1 (en)	2012-04-25	2024-06-24	Sanofi Sa	Microrna compounds and methods for modulating mir-21 activity
WO2013192576A2 (en)	2012-06-21	2013-12-27	Miragen Therapeutics	Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN104955950B (zh)	2012-09-26	2019-04-26	米尔克斯治疗学公司	具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта

2012
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
- 2012-04-25 PH PH1/2013/502199A patent/PH12013502199A1/en unknown
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/en active
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/en not_active Withdrawn
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/en active Application Filing
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active Active
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/en active Active
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/en active Active
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 CA CA3165397A patent/CA3165397A1/en active Pending
- 2012-04-25 CA CA2833615A patent/CA2833615C/en active Active
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Ceased
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
2013
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-23 MX MX2019003090A patent/MX2019003090A/es unknown
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
2017
- 2017-04-06 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
2018
- 2018-02-23 HK HK18102629.5A patent/HK1243130A1/zh unknown
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US20220098583A1/en active Pending
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL273381A (en)	2020-05-31
TW201300404A (zh)	2013-01-01
HRP20170557T1 (hr)	2017-06-16
TWI698445B (zh)	2020-07-11
AU2012249851A1 (en)	2013-10-31
KR20190063482A (ko)	2019-06-07
EA201391492A1 (ru)	2014-04-30
HRP20170557T2 (hr)	2020-02-21
TWI607016B (zh)	2017-12-01
RS61775B1 (sr)	2021-05-31
MX2013012452A (es)	2014-11-21
KR102055172B1 (ko)	2020-01-23
US20180155719A1 (en)	2018-06-07
US9790496B2 (en)	2017-10-17
EP3211082B1 (en)	2021-02-17
JP6320292B2 (ja)	2018-05-09
CY1120304T1 (el)	2019-07-10
KR20140033062A (ko)	2014-03-17
LT2702155T (lt)	2017-05-10
DK2702155T3 (en)	2017-05-01
HUE054129T2 (hu)	2021-08-30
PT3211082T (pt)	2021-04-28
PL3211082T3 (pl)	2021-08-02
ES2621863T9 (es)	2020-02-13
AU2022203067A1 (en)	2022-05-26
EA025894B1 (ru)	2017-02-28
EP3211082A1 (en)	2017-08-30
BR112013027187A2 (pt)	2017-06-06
PH12013502199A1 (en)	2014-01-27
PL2702155T3 (pl)	2017-09-29
NZ717921A (en)	2017-09-29
MX2019003090A (es)	2019-07-18
US20220098583A1 (en)	2022-03-31
AU2020201403A1 (en)	2020-03-12
EP2702155A1 (en)	2014-03-05
MX2022000212A (es)	2022-04-01
UA115652C2 (uk)	2017-12-11
JP2018121646A (ja)	2018-08-09
LT3211082T (lt)	2021-05-10
US20160138016A1 (en)	2016-05-19
CA3165397A1 (en)	2012-11-01
US20120270928A1 (en)	2012-10-25
AU2012249851B2 (en)	2017-06-08
US20200291400A1 (en)	2020-09-17
PT2702155T (pt)	2017-04-03
MY187685A (en)	2021-10-11
IL229032B (en)	2021-01-31
US20140107183A1 (en)	2014-04-17
SI3211082T1 (sl)	2021-08-31
US9181547B2 (en)	2015-11-10
JP2014518619A (ja)	2014-08-07
EP2702155B9 (en)	2020-01-01
EP3933040A1 (en)	2022-01-05
IL229032A0 (en)	2013-12-31
DK3211082T3 (da)	2021-05-10
EP2702155B1 (en)	2017-02-01
CN113151272A (zh)	2021-07-23
CN103620035B (zh)	2021-04-23
NZ616748A (en)	2016-03-31
TW201811812A (zh)	2018-04-01
IL266529A (en)	2019-07-31
AU2017219156B2 (en)	2020-01-02
ES2868950T3 (es)	2021-10-22
CA2833615C (en)	2022-08-30
AU2012249851A8 (en)	2013-11-14
CN113249381A (zh)	2021-08-13
MX2019003089A (es)	2019-07-18
HUE031595T2 (en)	2017-07-28
US20140329887A1 (en)	2014-11-06
ES2621863T3 (es)	2017-07-05
WO2012148952A1 (en)	2012-11-01
SI2702155T1 (sl)	2017-07-31
CO6821889A2 (es)	2013-12-31
MX2022006595A (es)	2022-07-01
SG194636A1 (en)	2013-12-30
MY175336A (en)	2020-06-19
US8912161B2 (en)	2014-12-16
AU2017219156A1 (en)	2017-09-21
CL2013003105A1 (es)	2014-08-01
CN103620035A (zh)	2014-03-05
HRP20210616T1 (hr)	2021-05-28
CA2833615A1 (en)	2012-11-01

Publication	Publication Date	Title
IL273381A (en)	2020-05-31	MicroRNA compounds and methods to modulate mir-21 activity
ZA201407228B (en)	2017-05-31	Microrna compounds and methods for modulating mir-21 activity
GB2492888B (en)	2016-02-10	Catalyst and method for its preparation
PT3636274T (pt)	2024-10-17	Composições para modular a atividade das citocinas gama-c
HRP20171424T1 (hr)	2017-11-03	Namotani nosač kolagena
IL228546A0 (en)	2013-12-31	fermentation process
EP2736588A4 (en)	2015-06-10	ELECTROSTIMULATION SYSTEM
GB201112231D0 (en)	2011-08-31	Micro-organism
SG11201403280PA (en)	2014-07-30	Bioreactor
EP2864469A4 (en)	2016-05-18	BIOREACTOR CARTRIDGE AND SYSTEM
IL228700A0 (en)	2013-12-31	A method for modulating cytokine activity
GB201108165D0 (en)	2011-06-29	Bioreactor chamber and method
GB201109849D0 (en)	2011-07-27	Modulation
GB201122254D0 (en)	2012-02-01	Bioreactor chamber and method
AU2011011V (en)	2012-09-04	FFV1 Ficus obliqua
GB201111898D0 (en)	2011-08-24	Bioreactor chamber and method